Drugs / PROTOXIN
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04996810 | Dec 2020 → Apr 2021 | — | Protox Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06124794 | Dec 2023 → Feb 2024 | — | Protox Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05364580 | Mar → Jun 2023 | — | Protox Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROTOXIN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05364580 ↗ |
| Known as | Clostridium botulinum toxin type A | “PROTOXIN 100U (Clostridium botulinum toxin type A)” NCT06124794 ↗ |
| Modality | Protein / enzyme biologic | “Botulinum toxin Type A” NCT05364580 ↗ |
| Route | Other | “PROTOXIN will be injected to 5 glabellar lines” NCT06124794 ↗ |